Sunlenca

Warnings and Precautions for Sunlenca

Sunlenca does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.

Immune Reconstitution Syndrome

In patients treated with combination antiretroviral therapy, including Sunlenca, immune reconstitution syndrome can occur, sometimes triggering an inflammatory response to residual or previous infections.

Long Residual Drug Concentrations

Sunlenca can remain in the body for up to 12 months or longer after discontinuation, which has implications for resistance if a fully suppressive regimen is not maintained. This should be carefully considered when planning subsequent therapy.

Injection Site Reactions

Injection-site reactions, including nodules and induration at the injection site, may occur and can be slow to resolve.

How to Access Sunlenca in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation and Availability of Sunlenca

Sunlenca is manufactured and marketed by Gilead Sciences. It is sourced through authorized distribution channels for patients seeking named-patient import into India.

Required Documentation

Patients typically need a valid prescription from a treating infectious disease specialist confirming HIV-1 diagnosis, treatment history, and resistance testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.

Availability

As an FDA-approved therapy for multidrug-resistant HIV-1, Sunlenca is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.

Sourcing and Delivery of Sunlenca

NPP sources Sunlenca directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.

Storage and Handling

Sunlenca should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit for both the oral and injectable formulations.

Delivery Timelines

Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.

Availability of Sunlenca Across Major Cities in India

Patients across India can access Sunlenca through NPP's regulated import pathway, with infectious disease specialists in major cities supporting the treatment process.

Mumbai

Leading hospitals in Mumbai support infectious disease care coordination and documentation for Sunlenca access.

Delhi

Delhi's major hospitals assist patients with prescription support and documentation for Sunlenca.

Bangalore

Bangalore's specialist network offers access coordination for eligible HIV-1 patients seeking Sunlenca.

Chennai

Chennai-based infectious disease specialists coordinate Sunlenca access alongside comprehensive HIV care.

Hyderabad

Hyderabad's care institutions support patients pursuing Sunlenca therapy.

Kolkata

Kolkata's specialist centers help coordinate documentation and treatment access for Sunlenca.

Pune

Pune-based specialists assist with prescription support and Sunlenca treatment planning.

Ahmedabad

Ahmedabad's specialty hospitals support the import and treatment process for Sunlenca.

Kochi

Kochi's specialist units assist patients with the documentation needed for Sunlenca access.

Chandigarh

Chandigarh's care centers support Sunlenca treatment coordination for patients from North India.

Jaipur

Jaipur's specialists help patients navigate the Sunlenca access process.

Lucknow

Lucknow-based centers assist patients pursuing Sunlenca therapy.

Bhubaneswar

Bhubaneswar's institutions support access to Sunlenca for eligible patients.

Guwahati

Guwahati's specialists help coordinate Sunlenca access for patients across the Northeast.

Patients in other cities across India can also access Sunlenca through NPP's nationwide coordination network.